Breaks Categories: News

ThursdayMar 02, 2017 12:32 pm

NetworkNewsBreaks – Bridgeline Digital, Inc. (NASDAQ: BLIN) Secures Three-Year Deal with Top Regional Medical Group for iAPPS Platform

Bridgeline Digital (NASDAQ: BLIN) this morning announced that a top regional multi-specialty medical group has chosen Bridgeline’s iAPPS Platform to power its online portal and marketing automation. The medical group has agreed to a three-year SaaS subscription to iAPPS Experience Manager Pro, Bridgeline’s comprehensive experience management suite. The platform includes web content management and digital marketing automation, as well as associated professional services. Additionally, the company will develop a custom online portal for the medical group’s multiple locations. “Experience Manager Pro provides the optimal blend of features to manage website content which engages existing patients while in parallel driving new…

Continue Reading

ThursdayMar 02, 2017 11:50 am

NetworkNewsBreaks – Tonix (NASDAQ: TNXP) Reports Successful Synthesis of Pre-Clinical Smallpox-Preventing Vaccine Candidate TNX-801

Shares of Tonix Pharmaceuticals Holding (NASDAQ: TNXP) gained 4% this morning as the company, along with researchers from the University of Alberta, announced the successful synthesis of a potential smallpox-preventing vaccine. The vaccine candidate, TNX-801, is a live form of horsepox virus (HPXV) that has demonstrated protective vaccine activity in mice. HPXV was synthesized at the University of Alberta, with Dr. Lederman as co-investigator of the research and co-inventor of the TNX-801 patent. Per the research and development agreement, Tonix wholly owns the synthesized HPXV virus stock and related sequences. Tonix has initiated vaccine manufacturing activities to support further nonclinical…

Continue Reading

ThursdayMar 02, 2017 11:44 am

NetworkNewsBreaks – ProBility Media Corp. (PBYA) Announces Collaboration to Provide Employment for Adults with Disabilities; Shares Spike 13%

Shares of ProBility Media Corp. (OTCQB: PBYA) are up 13% mid-morning after the company announced a new initiative with MainStreet Opportunities and Celebration Company of Jewish Family Services. MainStreet Opportunities is an employment program that helps adults with disabilities find and uphold employment, while Celebration Company is a transitional employment program for adults living with disabilities. ProBility’s wholly-owned subsidiary, One Exam Prep, has implemented an optional service to its line of study materials, now offering study materials with highlights and tabs, making it easier to review and study the exam preparation materials. Under the new initiative, One Exam Prep will…

Continue Reading

ThursdayMar 02, 2017 10:17 am

NetworkNewsBreaks – Stealth Technologies, Inc. (STTH) Announces Completion of Five New Products

Security and personal protection company Stealth Technologies, Inc. (OTCQB: STTH) this morning announced the completion of five new products that are now awaiting market rollout. The products are currently undergoing final review by a large direct response retailer’s quality assurance and legal department in order to ensure that the marketing claims associated with each product are accurate when compared to actual performance levels. This ongoing review will also ensure that the company’s existing inventory meets all necessary quality control parameters. “The new products range from consumer electronics to additional security and safety products,” Brian McFadden, CEO of Stealth Technologies, stated…

Continue Reading

WednesdayMar 01, 2017 2:33 pm

NetworkNewsBreaks – Cinedigm (NASDAQ: CIDM) Partners with The WHAM Network to Launch Global Gaming and eSports Streaming Network

Cinedigm (NASDAQ: CIDM) and The WHAM Network Inc. have entered a partnership to launch The WHAM Network, a 24/7 streaming channel providing news, information and entertainment focused on the global eSports and gaming lifestyle. The network will be operated and marketed by the two companies, and it is expected to launch in the third quarter of 2017. The channel will be available across all major connected mobile devices, gaming consoles, and set top boxes. The companies are currently in talks with additional platforms, skinny bundle providers, and cable operators in order to make the channel broadly available on all modes…

Continue Reading

WednesdayMar 01, 2017 11:50 am

NetworkNewsBreaks – Skyline Medical, Inc. (NASDAQ: SKLN) Shares Skyrocket on Innovative Technology Contract from Vizient, Inc. for STREAMWAY® System

Skyline Medical (NASDAQ: SKLN) shares are up 43% after the company announced it has received an Innovative Technology contract from Vizient, Inc. for its FDA-approved STREAMWAY® System for automated, direct-to-drain medical fluid disposal. Vizient is the largest, member-driven health care performance improvement company in the country with an annual purchasing volume of almost $100 billion. Hospital experts with expertise in this category who serve on one of Vizient’s member-led councils recommended STREAMWAY, which resulted in the contract. Innovative Technology contracts are reserved for technologies that demonstrate an ability to enhance clinical care or patient safety while improving an organization’s care…

Continue Reading

TuesdayFeb 28, 2017 12:25 pm

NetworkNewsBreaks – Neuralstem, Inc. (NASDAQ: CUR) Preclinical Data of NSI-189 Published in Journal of Cellular Physiology

Neuralstem’s (NASDAQ: CUR) preclinical data on NSI-189 was recently published in the Journal of Cellular Physiology. The study demonstrated that NSI-189 improved behavioral function recovery and enhanced hippocampal synaptic plasticity in stroke-induced animals during the 12-week treatment period, which was maintained up to 24 weeks post-stroke. The study demonstrated that in neurologic and motor deficit tests, the animals treated with NSI-189 performed significantly better than the placebo animals. Additionally, the animals treated with NSI-189 continued to improve during the second 12-week period even in the absence of drug treatment. Histological assessment of stroke-induced brains from NSI-189-treated subjects suggest that NSI-189…

Continue Reading

TuesdayFeb 28, 2017 9:35 am

NetworkNewsBreaks – ChineseInvestors.com, Inc. (CIIX) Presenting this Morning at the National Investment Banking Association Conference

Market analysis company ChineseInvestors.com, Inc. (OTCQB: CIIX) this morning announced that its management team will be presenting at the National Investment Banking Association Conference, which is currently underway at the Westin New York Grand Central Hotel in Midtown Manhattan. The company will be presenting alongside the WallStreet Research™ team, who is sponsoring ChineseInvestors.com’s participation at the event. Additionally, WallStreet Research™ has organized, for the CIIX management team, a collection of one-on-one meetings with prospective investors for later in the day at the Penn Club in New York. Interested parties can review ChineseInvestors.com’s presentation materials from the conference by visiting the…

Continue Reading

MondayFeb 27, 2017 12:07 pm

NetworkNewsBreaks – Cellectar Biosciences, Inc. (NASDAQ: CLRB) Reports Positive Data from Phase I Trial of CLR 131 in Multiple Myeloma; Shares Higher

Cellectar Biosciences (NASDAQ: CLRB) this morning issued a positive update of its phase I clinical study of CLR 131 in patients with relapsed or refractory multiple myeloma. The data show that the 25 mCi/m2 dose was safe and well tolerated, and that adverse events were similar to those in the previous two cohorts. All four cohort 3 patients achieved stable disease and continue to be followed for progression-free survival (PFS) and median overall survival (mOS). While it is premature to report survival-related efficacy data from cohort 3, all patients in cohorts 1 and 2 continue to experience overall survival benefit. …

Continue Reading

MondayFeb 27, 2017 12:04 pm

NetworkNewsBreaks – Pieris Pharmaceuticals (NASDAQ: PIRS) Grants ASKA Pharmaceutical Exclusive Option to License Anemia Drug in Japan

Pieris Pharmaceuticals (NASDAQ: PIRS) this morning announced that it has granted ASKA Pharmaceutical Co., Ltd. an exclusive option to license development and commercial rights to Pieris' anemia drug, PRS-080, in Japan and certain other Asian markets following completion of a multi-dose phase 2a study in dialysis-dependent anemia patients. Per the agreement, Pieris will immediately receive an option payment of $2.75 million. Following an analysis period after the completion of the planned phase 2a study conducted by Pieris, ASKA may exercise its option to obtain an exclusive license to develop and commercialize PRS-080 in Japan, South Korea and certain other Asian…

Continue Reading